Company intelligence / Profile preview

XRA 7

South San Francisco, California, United States

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Xaira launched in May 2024 with foundational AI models (RFdiffusion and RFantibody) for protein and antibody design. RFdiffusion demonstrated the ability to design protein drugs binding to influenza in weeks. RFantibody was published as a preprint in March 2024, capable of binding to coronaviruses and influenza.

Therapeutic areas: Other
Modalities: Protein design-based therapeuticsAntibody designSmall molecule design (in development)
Industry: Biotech

Partnerships

Technologies and personnel from Illumina's functional genomics R&D effortproteomics group from Interline Therapeutics

Beyond the preview

Go deeper on XRA 7.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XRA 7.

Explore the full profile